{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:04:41Z","timestamp":1792083881238,"version":"4.4.0"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2025,8,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral neurotoxicity (OIPN) is higher for oxaliplatin doses &gt;3.09 mg per kg of lean body mass (LBM). This proof-of-concept, multicenter, randomized trial assessed whether LBM-based oxaliplatin dose adjustment reduces OIPN (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03255434\">NCT03255434<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Among the patients with resected stage III colon cancer eligible for adjuvant leucovorin, fluorouracil, and oxaliplatin chemotherapy, those without LBM reduction received body surface area (BSA)\u2013based oxaliplatin doses (85 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , arm 1). Patients with reduced LBM were randomly assigned (1:1) to receive BSA-based (arm 2) or LBM-based oxaliplatin doses (3.09 mg\/kg LBM, arm 3). The primary end point was the percentage of patients without grade \u22652 OIPN in the first six cycles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In all, 33, 64, and 63 patients were enrolled in arms 1, 2, and 3, respectively (median age, 63 years; 52.5% of men; 89.3% Eastern Cooperative Oncology Group 0; 57.5% pT3; 60.6% pN1). The primary end point was achieved by 67.2% of patients in arm 3 versus 42.1% in arm 2 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .01). Longer grade \u22652 OIPN-free survival (hazard ratio [HR], 0.53 [95% CI, 0.34 to 0.84];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .01), longer time to grade \u22652 OIPN onset (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .006), higher cumulative oxaliplatin doses without grade \u22652 OIPN (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .044), and fewer oxaliplatin dose reductions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) were reported in arm 3. Relapse-free survival (HR, 1.05 [95% CI, 0.54 to 2.06]) and overall survival (OS; HR, 1.20 [95% CI, 0.36 to 3.92]) were similar in arms 2 and 3 (median follow-up of 38.6 months). Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 scores were better in arm 3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In adjuvant settings for stage III colon cancer, using an LBM-based oxaliplatin dose significantly reduces OIPN and improves quality of life without affecting relapse-free survival and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-24-02754","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:59:39Z","timestamp":1750435179000},"page":"2616-2627","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":26,"title":["Impact of Lean Body Mass\u2013Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03255434","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-2793","authenticated-orcid":true,"given":"Eric","family":"Assenat","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"},{"name":"Digestive Oncology Department, CHU Montpellier, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Ben Abdelghani","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, ICANS, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[{"name":"Biometric Unit, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Perrier","sequence":"additional","affiliation":[{"name":"Oncology Department, Saint Joseph Hospital, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza Khemissa","family":"Akouz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and GI Oncology, CH Saint-Jean, Perpignan, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Desgrippes","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology and Digestive Oncology, CH Saint-Malo, Saint-Malo, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[{"name":"Department of Digestive Oncology, Baclesse Center, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-1021","authenticated-orcid":true,"given":"Chlo\u00e9","family":"Janiszewski","sequence":"additional","affiliation":[{"name":"Clinical Research and Innovation Department, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-9603","authenticated-orcid":true,"given":"Thibault","family":"Mazard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Department, European Hospital of Marseille, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-4707","authenticated-orcid":true,"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology &amp; Digestive Oncology, INSERM EPICAD CTM 1231, University Hospital of Dijon Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Tetreau","sequence":"additional","affiliation":[{"name":"Department of Radiology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-2898","authenticated-orcid":true,"given":"Pierre","family":"Senesse","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition and Gastroenterology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6771"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0536"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00399-3"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0248"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000094376"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.8533"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.003"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.5911"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804283181717"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2297"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.621"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-082117-051723"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0546-5"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.05.011"},{"key":"e_1_3_10_18_2","doi-asserted-by":"crossref","unstructured":"Prado CMM Heymsfield SB: Lean tissue imaging: A new era for nutritional assessment and intervention. J Parenter Enteral Nutr 38:940-953 2014","DOI":"10.1177\/0148607114550189"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1998.85.1.115"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1139\/H08-075"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp605"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00744.2004"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.012"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3067"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2418-6"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2014.894103"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5360-7"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30950"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02463-2"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05227-7"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S195869"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/codi.12805"},{"key":"e_1_3_10_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2019.03.011"},{"key":"e_1_3_10_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.4010"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2693"},{"key":"e_1_3_10_36_2","unstructured":"Cancer du c\u00f4lon non m\u00e9tastatique. SNFGE 2024. https:\/\/www.snfge.org\/tncd\/cancer-du-colon-non-metastatique"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0106"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000323491"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-021-03995-7"},{"key":"e_1_3_10_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0355"},{"key":"e_1_3_10_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.010"}],"updated-by":[{"DOI":"10.1200\/jco-25-02239","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-02754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T19:59:29Z","timestamp":1761681569000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-02754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,8,10]]}},"alternative-id":["10.1200\/JCO-24-02754"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-02754","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,10]]},"assertion":[{"value":"2024-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}